Conexeu says CXU preclinical program completes 12-month P..O.F. phase, meets objectives
argenx SE Stock (ARGX) Moved Up by 16.67% on Aug 17: Drivers Behind the Movement
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
Achieve Life Sciences Stock Has Nearly Tripled in the Last Year. Now It Just Needs to Turn a Profit.
CERO THERAPEUTICS HOLDINGS INC C/WTS 14/02/2029 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 0
CERO THERAPEUTICS HOLDINGS INC C/WTS 13/02/2029 (TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -61.71